Author: News Direct

–News Direct–

With the everchanging global economy and tightening of crypto regulations by the SEC, the cryptocurrency market continues to have consolidated movements.

This year, memecoins have experienced a momentary rise but quickly fell alongside the overall market. Crypto enthusiasts have gradually learned from the market that a gambler's mindset is not the way to survive. Here are the most frequently asked questions from this year:

What are the more stable passive income options that can preserve the value of coins and generate substantial returns?

Secure and dependable investment products offered by exchanges have become highly coveted for portfolio allocation.

Exchanges like Huobi, Binance, OKX, and others have launched various interestbearing investment products.he challenge lies in choosing the right product among these offerings.

Guiding Principles

We are already halfway through 2023, how have you been progressing toward your goals for the year?

Regardless of whether you have achieved remarkable profits or mediocre returns, investors need a secure and trustworthy investment approach for their solid funds.

Simple but useful principles to choose financial products:

1. Larger exchanges are better than small ones.

Reason: It is the safety of your funds matter the most. Generally speaking, larger exchanges are more dependable in terms of security and compliance.

After the FTX fallout, exchanges choose to open their reserves to the public through auditable proof of reserves with a Merkle Tree, ensuring transparency.

Therefore, for enhanced security of your digital assets, it is advisable to select exchanges that regularly report Merkle Tree-based proof of reserves.

2. New financial products outperform old competitors.

Reason: New products often offer higher returns.

3. Exchanges with diverse product offerings surpass others

Reason: A professional standpoint unpacks that exchanges' proficiency in the passive income arena lies in whether the dual requirements of asset security and returns can be met.

How to Find a Financial Product that Suits You Well? (Take Huobi's Products for Example)

1. MaxEarn

Advantages: Flexible deposits and redemptions, secure asset management, and stable returns.

Applicable token: USDT (More options are coming)

Deposit amount requirement: 10,000 USDT

See below for APY and redemption fee rates:

Category	Detail	Fee Rate
APY	4.00 + 1.00 (bonus)	5.00
Tiered redemption fee rate	Holding duration: 180 days	0.50
	Holding duration: 180 days and 365 days	0.30%
	Holding duration: 365 days	0.00

Target users:

1. High Net Worth Individual Investors: If you have accumulated significant wealth and are seeking investment opportunities with high returns, this product is suitable for you as a robust long-term asset allocation strategy. It does contain short-term redemption fees.

2. Professional Investors: For institutional investors, fund managers, or other professional investors who can select high-quality passive income products based on market insights and investment experience, this product is well-suited as a stable and high-return investment option.

3. LongTerm Investors: If you have funds set aside for a longterm investmentsuch as retirement reserves or education funds for your children,and are open to committing these funds to passive income products over an extended period, this product is an excellent fit for you. It can help you hedge against shortterm market fluctuations while securing stable yields.

Please note: You should fully understand the product characteristics and earning features of MaxEarn, assess your risk tolerance, and consider factors like liquidity and redemption fees to ensure that the product aligns with your financial needs and investment horizon.

2. Regular Invest

Advantages: Regular investment plans help you earn in a convenient and effortless way

Shield yourself from market volatility, amass gains, and lower average costs.

Flexible investment portfolio: You can create a portfolio by investing in one crypto or multiple cryptos.

Tailored recurring cycle: You can select from 6 options including: 1 hour, 2 hours, 4 hours, daily, weekly, and monthly.

Applicable cryptos: 70 trending coins and tokens, such as BTC, ETH, and HT

The minimum deposit amount for a single-crypto portfolio is 15 USDTwhile for a multi-crypto portfoliois 100 USDT.

If the cryptocurrency you deposited has a corresponding Flexible product with the remaining subscription amount, it will be transferred to the Flexible product. If the available subscription amount is insufficient, a portion of your deposit will be transferred to the Flexible productwhile the rest will be transferred to your Spot account. If there is no Flexible product available for the crypto, it will be automatically transferred into your Spot account.

Target users:

1. Dollar cost averaging investors

2. People with less time to invest

3. Long term investors

4. Investors with a small budget

Regular Invest is suitable for individuals with limited investment experience and time, seeking long term growth and risk diversification. It is especially beneficial for investors who are willing to hold their investment portfolios for an extended period and regularly allocate funds.

3. Auto Invest Your Balance

Advantages: One click activation, flexible subscription and redemption, safe and stable, abundant applicable assets, and automatic compound interest

Applicable cryptos: All coins and tokens available on Huobi Earn

4. Two Options with Limited time APY

Advantages: Flexible deposits and redemptions, and high APYs

Target users: BETH and ETH holders who pursue high gains on their holdings

The BETH Flexible product offers up to 10% APY.

Product	Token	Subscription Amount	Est. APY
Flexible	BETH	0-10 BETH	10.00
		10-100 BETH	2.00
		100-5,000 BETH	1.00
		5,000 BETH	0.05

The ETH Flexible product provides 2%-6% APYs.

Product	Coin	Subscription Amount	Est. APY
Flexible	ETH	0-0.2 ETH	6.00
		0.2-1 ETH	5.00
		1 ETH	2.00

Why Huobi Passive Income Products?

Huobi meets the selection criteria we mentioned earlier:

1. Adequate security

Huobi is a well established andleading exchange. It regularly discloses 100% proof of reserves through the Merkle Tree mechanism.

Asset security is a top concern for everyone. Huobi completed the development of the Merkle Tree on December 2022 and adopted it for Proof of Reserves.It enables users to verify that their assets are fully backed (1:1) on the platform. The launch of this service realizes an open source verification of the Merkle Tree, wallet address ownership, and on-chain assets.

2. Constant pools of new financial products:

Huobi Earn has recently unveiled multiple new productsincluding MaxEarn, Regular Invest, Auto-invest Your Balance, and flexible products for BETH and ETH, offering up to 10% APY.

3. Comprehensive and extensive selection of financial options

Leveraging a robust risk management system and ensuring the security of user assets, Huobi Earn offers a diverse range of financial products to meet the increasing demands for the value appreciation of digital assets. Whether you're looking for earning opportunities for large assets or making regular investment plans, Huobi Earn is the perfect platform to find secure and suitable products.

It's worth noting that on June 8 2023, Huobi announced its latest Merkle Tree-based proof of reserves. Users can view Huobi reserves of BTC, ETH, BETH, TRX, USDT, and HT in detail on the asset audit page of Huobi's official website, including reserve ratio, Huobi wallet's assets, and user assets. Huobi's reserves are updated monthly, with a snapshot taken on the 1st day of each month. The Merkle Tree data update is generally completed in the first week of the month.

Asset reserve security and transparent management are crucial for an exchange.

Huobi's dedication to asset security goes beyond the monthly disclosure of 100% proof of reserves through the Merkle Tree for the past six months. It is ingrained in every aspect of their business operations. On a decade-long crypto road, Huobi has maintained an impeccable record with no major incidents compromising asset security.

Huobi Earn is making continuous efforts on its journey to regain its position among the top 3 exchanges. With its profession, compliance, and security, Huobi Earn has introduced multiple products with efficient features. You can discover them by visiting Huobi's official website and navigating to Huobi Earn.

Looking back at the investment returns of cryptocurrencies in the past six months, it is evident that stable wealth management has been the least risky option. In the present situation, adopting stable wealth management strategies to achieve significant returns deserves the attention of every cryptocurrency investor.

About Huobi

Founded in 2013, Huobi has evolved from a crypto exchange into a comprehensive ecosystem of blockchain businesses that span digital asset trading, financial derivatives, wallets, research, investment, incubation and other areas. Huobi serves millions of users worldwide, with a business presence covering over 160 countries and regions across five continents. Its three development strategies – "global development, technology drives development, and technology for good" underpin its commitment to providing comprehensive services and values to global cryptocurrency enthusiasts.

Contact Details

Michael Wang

glo-media@huobi.com

Company Website

https://www.huobi.com/

View source version on newsdirect.com: https://newsdirect.com/news/crypto-financing-top-stable-passive-income-ideas-for-2023-646225801

Huobi

COMTEX_435982603/2655/2023-06-25T22:34:47

–News Direct–

SINGAPORE – Media OutReach – 26 June 2023 – Oasys, a gaming-optimised blockchain, today announced a partnership with Rakuten Wallet Inc., a renowned Japanese crypto exchange company. Rakuten Wallets addition to Oasys dynamic network of validators marks a pivotal leap in Oasys ongoing journey to revolutionise Web3 within the gaming industry.

Rakuten Wallet, well-regarded as a crypto asset exchange service provider for its spot and margin trading services, will be entering the Web3 sphere as an Oasys validator in this new initiative. Moreover, possibilities of linking the Oasys ecosystem with Rakuten Wallet's developed services are currently under exploration.

This partnership aims to redefine the gaming experience by integrating the endless potential of blockchain technology. In line with this, Rakuten Wallet will provide staking and validation services for Oasys proof-of-stake network, a multi-layered, EVM-compatible public blockchain. This collaboration aligns with Oasyss commitment to offering a highly efficient and stable gaming development environment, characterised by low gas fees and high transaction speeds.

Daiki Moriyama, Director of Oasys, said: Rakuten Wallets trailblazing entry into Web3, together with its proven expertise in service operations, wealth of know-how, and vast customer reach, will immensely contribute to the burgeoning Web3 sector in Japan. Their involvement as a validator on the Oasys Chain is just the beginning of a promising partnership. We foresee future collaborations, spawning new opportunities and transformation in the Web3 landscape.

Oasys has continually fortified its stature as a gaming-focused blockchain through partnerships with several industry leaders, who have joined the network as validators across three rounds. The participation of industry giants such as SoftBank, KDDI, Nexon, and MIXI has propelled the Oasys chain to new heights, with Rakuten Wallets involvement further enriching this consortium.

Tatsuya Yamada, CEO of Rakuten Wallet, said: Oasys, Japans pioneering gaming-focused blockchain, promises an unsurpassed environment for gaming users and intellectual properties. As a forward-thinking tech company, we are thrilled to contribute as a validator. Additionally, we remain open to exploring further synergies with Oasys, especially in relation to Web3-orientated services.

The partnership will tap into Rakuten Wallets extensive expertise in strengthening network security and consensus protocol. This symbiosis between Rakutens robust economy and the Oasys ecosystem is anticipated to drive innovation, crafting novel solutions that align with the evolving demands of the Web3 gaming era.

About Oasys

Oasys is a blockchain-based game development platform that offers a highly scalable Layer 1 hub and specialized Layer 2 using Ethereum's Layer 2 scaling solution. The ecosystem provides game developers with a secure and scalable blockchain infrastructure for creating more efficient, secure, and interoperable games. Among Oasys validators are leaders in gaming and Web3, such as SEGA, Ubisoft, and Yield Guild Games, who act as initial validators in our Proof-of-Stake (PoS) based blockchain. Oasys' expert blockchain team, combined with the biggest names in gaming, is revolutionizing the gaming industry.

Oasys solves the challenges that game developers face when building blockchain-based games by focusing on creating an ecosystem for gamers and developers to distribute and develop games. The company's trifecta approach includes a fast network powered by the gaming community, a scalable network powered by AAA game developers, and a blockchain that provides the best user experience with fast transactions and zero gas fees. This approach prepares participants to enter the Oasys and play.

More information on Oasys is available at:

Website: https://www.oasys.games

Twitter: https://twitter.com/oasys_games

Discord: http://discord.gg/oasysgames

About Rakuten Wallet

Rakuten Wallet is a global technology company that provides a wide range of services, including e-commerce, digital content, fintech, mobile carrier services, and professional sports. With a commitment to innovation, Rakuten Wallet continues to explore and lead advancements in the Web3 industry.

Contact Details

Oasys

Media Contact

oasys@wachsman.com

View source version on newsdirect.com: https://newsdirect.com/news/rakuten-wallet-joins-oasys-blockchain-as-validator-alongside-softbank-kddi-nexon-and-mixi-878218395

Oasys

COMTEX_435981607/2655/2023-06-25T21:40:39

–News Direct–

Pioneering educational providers In the Footsteps of History, creators of a tech-forward social studies enrichment program that brings world history to life through the excitement of adventure and exploration, have partnered with Lumio, the digital learning tool used by millions around the world and created by global EdTech leader SMART. Through this new collaboration, more than 20 free In the Footsteps of History lessons, including Marco Polo and the Silk Road, the travels of Ibn Battuta and the legendary city of Timbuktu, and more will be available in Lumio, making the most of its interactive and engaging resources for exciting history education.

In the Footsteps of Historys immersive lessons, presented by world-famous explorers, fill a much-needed role in an often challenging subject to teach. The programs unique mix of documentary-quality videos https://inthefootsteps.org/the-ibn-battuta/, 3D games https://3dmap-itf.pages.dev/, https://patterns-itf.pages.dev/ and cutting-edge, web-based simulations powered by Ultisim provide a valuable teaching tool for building knowledge, expanding world views, and fostering respect for other cultures. With outstanding reviews for higher engagement, improved visualization, and elevated critical thinking, In the Footsteps of History ushers in a whole new era for the social studies classroom.

The power of technology to provide students with opportunities to visit places that they would not otherwise be able to is truly impressive, says explorer Denis Belliveau, CEO, and Founder of In the Footsteps of History. Our hope is that this will encourage more and more youth to go out and discover the world around them.

For middle and high school social studies educators who are looking to engage students with unique and immersive lessons, Lumio and In the Footsteps of History have teamed up to create a new resource category of original content https://suite.smarttech-prod.com/lumio-library/category/i1Iqf2 , utilizing Lumios collaborative and interactive game-based learning tools.

We are thrilled to work with the team at In the Footsteps of History to bring unique, immersive history learning into Lumio, supporting teachers and students with great content. Says Dan McMahon, Lumio Vice President of Software. Together, we have even more opportunities to bring learning to life and connect more students with engaging experiences.

In the Footsteps of History is presenting at ISTELive June 26-28 at booth #1466 and Lumio is presenting at booth #2718 at the Pennsylvania Convention Center.

New In the Footsteps of History 'Journeys' will be rolling out over the coming months.

ABOUT IN THE FOOTSTEPS OF HISTORY:

In the Footsteps of History is a tech-forward social studies enrichment program of multimedia units that bring history to life through the excitement of adventure and exploration.

Offered as complete units called Journeys with videos, web-based 3D games, and standards-aligned lesson plans, and augmented by additional immersive virtual reality (VR) Walkabouts, In the Footsteps of History promotes higher engagement, improved visualization, stronger comprehension, increased retention, and elevated critical thinking. For more information and free trials visit www.inthefootsteps.org or contact Lisa Taylor at 718-986-5104 or by email at lisa@inthefootsteps.

About Lumio

Lumio is a free, easy-to-use, digital learning tool that lets teachers transform lessons into active, collaborative learning experiences to engage students on their devices, wherever they are. With countless ways for students to engage and drive their own learning, Lumio is a perfect fit for educators who are looking for ways to increase interactivity, collaboration, and game-based learning. To learn more, visit www.golumio.com.

Contact Details

In the Footsteps of History

Lisa Taylor

lisa@inthefootsteps.org

Company Website

https://inthefootsteps.org/

View source version on newsdirect.com: https://newsdirect.com/news/pioneering-history-education-providers-announce-new-collaboration-with-global-edtech-leader-356318347

In the Footsteps of History

COMTEX_435958416/2655/2023-06-25T07:59:57

–News Direct–

Day four of the Royal Ascot 2023 is bound to be just as thrilling as the previous three days; just like the other days, day four will have seven races. One stand-out race on day four is the Group 1 Commonwealth Cup, which is only is only six furlongs long. If betting on day four interests you, why not check out some of the betting offers below?

Best Betting Sites

Bet365: Bet 10 Get 30

Bet365 has become one of the giants in the sports betting world, and it's not surprising given its huge range of games, promotions and sports betting markets. Users can find all of the popular sports betting options they could possibly want, including football, tennis and horse racing.

Min deposit requirement. Free Bets are paid as Bet Credits and are available for use upon settlement of qualifying bets. Min odds, bet and payment method exclusions apply. Returns exclude Bet Credits stake. Time limits and T&Cs apply.

William Hill: Bet 10 Get 30

Another beast in the industry is William Hill. This sports betting site is best known for its extensive and generous promotional page. Which includes its current bet 10 get 30 offer for the Royal Ascot.

18+. Play Safe. From 00:01 on 18.10.2022. 30 bonus. New customers only. Minimum 10 stake on odds of 1/2 (1.5) or greater on sportsbook (excluding Virtual markets). Further terms apply.

Betfred: Bet 10 Get 40

This site is known for having detailed and helpful FAQs and customer support service, which helps players with everything they could need. Some guides you may find include how to claim their current bet 10 get 40 offer, how to bet on the Royal Ascot and a guide to betting odds.

New 18+ UK customers only. Register using the promo code WELCOME40, deposit and place first bet of 10+ on Sports (cumulative Evens+) within 7 days of registration. First bet must be on Sports. 30 in Free Bets and 10 in Free Spins (50x20p) credited within 10 hours of bet settlement. Free Bet stakes are not included in any returns. Bonuses have a 7-day expiry. Payment restrictions apply. SMS verification and/or Proof of I.D and address may be required. Full T&Cs apply.

BetVictor: Bet 10 Get 40

Not only does BetVictor offer a range of payment options and sport betting markets but also offers great promotions. For example, its current bet 10 get 40 offer rewards players for placing a first bet with them; the free bets cash bonus can then be used to be around the site, including on betting options for the Royal Ascot.

18+ New customers only. Opt in, bet 10+ at odds 2.00+, in 7 days. No cash out. Get 4x 10 Free Bets on selected events. 7 day bonuses expiry. Card payments only. T&Cs Apply, see below. begambleaware.org | Please gamble responsibly

Betway: Matched Free Bet if your First Acca Loses

Betway offers the most unique Royal Ascot promotion of all the sites on our list. What this offer means is that if you are to place an acca (accumulator) bet and it loses, you will receive a 30 free bets bonus to use on the Royal Ascot.

*New UK customers only. Min Deposit: 5. Maximum Free Bet: 30. First bet on a Football or Horse Racing multiple with 3+ selections. Overall odds: 3.00 (2/1) or higher. Free Bets available upon settlement of the qualifying bet. This is offer is valid for 7 days from your new account being registered. 50 Bonus Spins credited on placement of qualifying Acca bet.50x bonus wagering applies as do weighting requirements, bonus Spins only available on selected games and expires 7 days after being awarded. Debit card deposits only (exclusions apply). 18+. BeGambleAware.org. Bet The Responsible Way. Full terms apply.

18+ Gambling Can Be Addictive. Please Play Responsibly. BeGambleAware GamStop Gambling Commission

The Royal Ascot Day 4 Races

Like the previous days, there will be seven races in total on day four; we have listed the name, time, distance and age group of each of these races below.

Race:	Time	Distance	Runners	Age
Albany Stakes (Group 3)	14:30	Six Furlongs	27	2 (Fillies)
Commonwealth Cup (Group 1)	15:05	Six Furlongs	16	3 (Colts & Fillies)
Duke of Edinburgh Stakes (Handicap)	15:40	One Mile, Four Furlongs	59	3+
Coronation Stakes (Group 1)	16:20	Old Mile (1m, 7f, 213y)	9	3 (Fillies)
Sandringham Stakes (Handicap)	17:00	One Mile	53	3 (Fllies)
King Edward VII Stakes (Handicap)	17:35	One Mile, Four Furlongs	20	3 (Colts & Geldings)
Palace of Holyroodhouse Stakes (Handicap)	18:10	Five Furlongs	60	3

Royal Ascot Day 4 Tips

Starting off the fourth day is Albany Stakes, Group 3; this is a six-furlong group with fillies ages two only; this is another day on which a fast race kicks off the events of the day.

Following this is the Commonwealth Cup, which is the most popular of the day. This race was established back in 2015 and is exclusively for fillies and colts aged three. Like the previous race, it is also six furlongs.

Up next is the Duke of Edinburgh Handicap, a handicap race when each horse is allocated a weight baes on its ability to try and equalise every horse's chance of winning. The higher the horse's handicap, the more weight they are required to carry.

The halfway point of the day, race four, is the Coronation Stakes which is across one mile and can only be run by fillies aged three.

After this race is the Sandringham Stakes race which has the same conditions as the previous Britannia Stakes race on day three but is only open to three-year-old fillies, it is often shocking how much effect the conditions of a race have on a horses chance of winning, and this can include heat, rain or cold. For example, Hayley Tuner won at 33/1 odds two years running due to conditions and the effects it had on other horses.

Race six is the King Edward VII Stakes which is a race run just over one mile (one mile and four furlongs). It is only open to Colts and Gelding, which are three years old.

Last, in the day, race seven, is the Palace of Holyroodhouse Stakes, which is another handicap race. This race is only five furlongs, making it the quickest of the day. This is the largest race of the day, with sixty runners, all aged three.

Conclusion

In conclusion, bettors and racegoers should expect a similar fun and thrilling experience as they will have had on the previous three days. This is the day with the races with the most runners; one race even has a whopping sixty runners, which is the second largest race of the five days; the first is the Wokingham Stakes race on day five which has 66 runners.

Frequently Asked Questions (FAQs)

What is the best day at the Royal Ascot 2023?

The best day for you will depend on what races you like to watch, however, many racegoers and bettors enjoy the Gold Cup race, which this year will take place on Thursday, the 22nd of June (day 3).

Which royals will be at the Royal Ascot 2023?

King Charles III and his wife, Queen Camilla, will be present for all five days of the event. Other royals that can be expected are Princess Anne, the Duke of Edinburgh, the Duke and Duchess of Cambridge and Cornwall and many more.

What days are Royal Ascot 2023?

The Royal Ascot 2023 will take place on Tuesday the 20th of June, and will last five days, to Saturday the 24th of June.

Can I bet on the Royal Ascot Online?

Yes, many online sportsbooks will offer Royal Ascot betting odds, and others will offer promotions all well, such as; Bet365, William Hill, Betfred, BetVictor and Betway.

What dates are the Royal Ascot next year?

Although the dates for next years Royal Ascot are not yet confirmed, we can tell you that it will likely take place around mid-June.

Contact Details

Acroud Media

info-media@acroudmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/royal-ascot-day-4-free-bets-and-betting-offers-772809562

Acroud Media

COMTEX_435864305/2655/2023-06-23T05:00:06

–News Direct–

Cascade Copper CEO Jeff Ackert joined Proactive's Steve Darling to share news it has signed a Letter of Intent to purchase 90% interest in the Copper Plateau project in south-central British Columbia.

The company says the project is near the historic Brenda Copper Mine and about 40 km west of Kodiak Coppers MPD project.

Ackert told Proactive more about the reason the company decided to acquire this project and if the company is planning any work this year. Ackert also talked about the recent work, including Lidar, the company has done on its flagship Rogers Creek project.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/cascade-copper-adds-to-portfolio-by-signing-loi-to-purchase-interest-in-copper-plateau-project-340104597

Cascade Copper Corp

COMTEX_435881169/2655/2023-06-23T16:23:39

–News Direct–

Liberty Star Minerals President and CEO Brett Gross and independent geologist Jim Bryce join Natalie Stoberman from the Proactive newsroom to discuss the findings from the independent evaluation of the Red Rock Canyon Gold Project conducted by Bryce.

Bryce says the evaluation reveals an intact gold deposit from the source of mineralization to the surface, indicating great potential. Moving forward, Bryce says he recommends a detailed sampling program to establish resources and initiate metallurgical studies for optimizing recovery methods.

Gross says the evaluation validates the company's previous work and highlights the availability of permits for their initial area of interest.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/liberty-star-minerals-shares-next-steps-after-positive-evaluation-of-red-rock-canyon-gold-project-557028606

Liberty Star Uranium & Metals Corp.

COMTEX_435877696/2655/2023-06-23T13:41:18

–News Direct–

Blackwolf Copper and Gold CEO Morgan Lekstrom joined Steve Darling from Proactive to share news about this appointment as CEO. This after Blackwolf announced it had acquired Optimum Ventures.

The addition of Optima Ventures brings experienced professionals like Rob McLeod and Frank Giustra on board, along with promising drill targets. Blackwolf aims to establish a footprint in the Golden Triangle and upcoming catalysts include drilling at the Cantoo area in July.

Lekstrom shared with Proactive more about his role with the company and his background which has seen him working 17 years in the industry in senior roles from executive management, project management, operations, and engineering management.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/blackwolf-copper-and-gold-announces-morgan-lekstrom-as-new-ceo-576675488

Blackwolf Copper and Gold

COMTEX_435876713/2655/2023-06-23T13:15:43

–News Direct–

Defiance Silver CEO Chris Wright and executive vice president Doug Cavey joined Steve Darling from Proactive to share news the company is awaiting more results from the Zacatecas Project in Mexico after releasing results that showed the widest width drilled to date at 41.83 metres of 157.30 g/t silver.

The company has recently completed a 5,000-meter drill program and is now preparing an updated resource estimate.

Wright telling Proactive the company will look to have the updates resource by the end of the year.

Cavey also added the historical work and the past three years of exploration have provided valuable insights and guidance for future mining potential in the district.

Contact Details

Proactive Investors

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/defiance-silver-releases-positive-drill-results-from-work-at-the-zacatecas-project-767092954

Defiance Silver Corp

COMTEX_435876561/2655/2023-06-23T13:11:26

–News Direct–

FinancialNewsMedia.com News Commentary – Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used in the treatment. The increase in the geriatric population is one factor driving the pancreatic cancer treatment market growth. The incidence is significantly higher in the geriatric population above 65 years of age compared to other types of cancers. The increase in the number of patients suffering from the condition has increased the demand for the drugs used in treatment. A report from Fortune Business Insights said that this factor will be driving the growth for the next several years. The report projected that the global pancreatic cancer treatment market size was valued at USD 2.48 billion in 2022 and will grow to USD 6.85 billion by 2029, exhibiting a CAGR of 15.7% during the forecast period. The report continued: Companies engaged in manufacturing cancer drugs have increased their focus on R&D activities to develop new drugs for pancreatic cancer treatment. Additionally, the companies operating in the market have received approval from several regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA) (U.K.), among others, thereby propelling the growth of the market. Moreover, new testing technologies are being adopted by hospitals and diagnostic centers to diagnose cancer. The increase in the diagnosis rates is driving the demand for drugs, thereby providing opportunities for the players. Active biotech and pharma companies in the markets this week include Oncolytics Biotech Inc. (ONCY ONC.TSX), Sotera Health Company (NASDAQ: SHC), Centessa Pharmaceuticals plc (NASDAQ: CNTA), Bristol Myers Squibb (NYSE: BMY), Gilead Company (NASDAQ: GILD).

Fortune Business Insights continued: Shifting the focus of key players in extensive R&D activities to develop new drugs and an increase in funding for cancer research led to the development of new drugs for treatment. Additionally, several pharmaceutical companies are involved in clinical trials to develop new drugs and explore the potential of the molecule to treat the disease. It concluded: Thus, with the increased funding for R&D activities, companies are focused on developing new drugs, thereby contributing to the overall rise in demand for drugs for pancreatic type of cancer treatment through 2029.

Oncolytics Biotech Inc. (ONCY – ONC) BREAKING NEWS: Oncolytics Biotechs Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial

• Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial
• If successful, new clinical study expected to support approval of pelareorep in combination with a checkpoint inhibitor, gemcitabine, and nab-paclitaxel in first-line metastatic pancreatic cancer
• Data presented at SITC 2022 showed a near tripling of overall response rate for pelareorep + gemcitabine + nab-paclitaxel + a PD-L1 inhibitor compared to historical control trials

Oncolytics Biotech (trading on the NASDAQ under the Symbol ONCY and the TSX exchange under ONC) today announced pelareorep has been selected for inclusion as a new investigational treatment in Precision PromiseSM, an innovative adaptive Phase 3 clinical trial. The Precision Promise study is designed to evaluate pelareorep in combination with a checkpoint inhibitor and the chemotherapeutic agents gemcitabine and nab-paclitaxel. If successful, the clinical study is expected to support approval of the studied combination as a treatment for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).

Precision Promise has a primary endpoint of overall survival and can include multiple investigational treatments as well as control arms evaluating: (1) gemcitabine plus nab-paclitaxel or (2) mFOLFIRINOX. Each investigational therapy is subject to pre-specified interim analyses prior to proceeding to the registrational portion of the trial. This design, which was developed with guidance from the U.S. Food and Drug Administration, minimizes the number of participants needed to generate licensure-enabling data, thereby accelerating late-stage development by up to two years and reducing costs compared to non-platform trials.

We are delighted at being selected by the Precision Promise panel of experts, said Dr. Matt Coffey, President, and Chief Executive Officer of Oncolytics Biotech. Our next step is to engage with stakeholders to finalize the protocol for Precision Promises pelareorep-containing investigational treatment so that we can enter into this study. We are thrilled to have the opportunity to leverage Precision Promise, which we expect will allow us to reduce the time and costs needed to reach a potential approval.

Julie Fleshman, JD, MBA, President and CEO of PanCAN commented, With a five-year survival rate of 12%, pancreatic cancer patients cannot afford to wait for new treatment options. This urgent unmet need was the driving inspiration behind the Precision Promise platform trial, which was designed specifically to identify, accelerate, and de-risk the development of promising pancreatic cancer treatments. We are thrilled to be bringing pelareorep into Precision Promise as a new investigational therapy to study against the current standard of care.

Dr. Thomas Heineman, Chief Medical Officer of Oncolytics Biotech, commented, Prior trials in pancreatic cancer show pelareorep-based combinations outperforming historical controls on key metrics such as one and two-year survival and objective response rate. In addition, mechanistic data from these studies highlight how pelareoreps immunologic mechanism of action allows it to synergize with chemotherapy and checkpoint inhibition in this indication. I look forward to working with the Precision Promise team of investigators to seek to confirm the therapeutic value of pelareorep in a randomized setting so that we can potentially provide pancreatic cancer patients with a new treatment option. CONTINUEDRead this full press release and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/

Other recent breast cancer developments in the biotech industry of note include:

Sotera Health Company (NASDAQ: SHC) recently announced that the opt-in process for the January 2023 settlements of ethylene oxide claims against Sterigenics in the Circuit Court of Cook County, Illinois is complete and Sterigenics has elected to proceed with the settlements.

879 of the 882 claimants eligible to participate in the settlement program have opted in. The settling claimants and Sterigenics will now request that the Circuit Court enter an order confirming that these are good-faith settlements under the Illinois Contribution Among Joint Tortfeasors Act. The settlement funds will be released from escrow for disbursement to the settling claimants ten days after the Court enters the anticipated good-faith determination and their claims against Sterigenics will subsequently be dismissed with prejudice. The lawsuits of the three claimants who opted out of the settlement will proceed to pretrial discovery pursuant to a schedule to be set by the Circuit Court.

Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia B, with or without inhibitors.

"We are pleased with the FDAs decision to grant Fast Track designation for SerpinPC as we continue to advance the PRESent registrational studies for SerpinPC in hemophilia B, said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. This designation is important recognition of SerpinPCs novel mechanism of action and underscores the critical need for new treatment options for persons with hemophilia B. We believe SerpinPC has the potential to be a first-in-class subcutaneously administered therapy with a differentiated safety profile for persons with hemophilia B, subject to review and approval.

Bristol Myers Squibb (NYSE: BMY) announced the first disclosure of primary analysis results from two pivotal studies, TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory follicular lymphoma (FL) and the relapsed or refractory mantle cell lymphoma (MCL) cohort of TRANSCEND NHL 001, an open-label, multicenter, Phase 1, single-arm, seamless-design study evaluating Breyanzi. These data were presented in late-breaking oral presentations at the 2023 International Conference on Malignant Lymphoma (ICML) on Saturday, June 17.

"With Breyanzi, were dedicated to delivering a CAR T cell therapy with a differentiated profile to transform outcomes for some of the most difficult-to-treat lymphomas," said Anne Kerber, senior vice president, head of Cell Therapy Development, Bristol Myers Squibb. "Based on results from TRANSCEND FL and TRANSCEND NHL 001, Breyanzi continues to demonstrate the ability to elicit significant deep and durable responses alongside a manageable safety profile, potentially addressing areas of high unmet need and reinforcing our commitment to advancing innovative solutions for the broadest array of hematologic malignancies of any CD19-directed CAR T cell therapy."

Kite Pharma, Inc., a Gilead Company (NASDAQ: GILD) announced that the Marketing Authorization in Japan for Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.

This follows the announcement made by Daiichi Sankyo and Kite Pharma, Inc. in December 2022 about changes to their initial 2017 partnership whereby Daiichi Sankyo obtained the Marketing Authorization for Yescarta. With this completion of the Marketing Authorization transfer, the sales and promotion activities of Yescarta in Japan now will be managed by the Kite Cell Therapy Business Unit of Gilead Sciences K.K.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

SOURCE Financialnewsmedia.com

Contact Details

Financial News Media

Media Contact

+1 561-325-8757

editor@financialnewsmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/pancreatic-cancer-trials-and-new-treatments-receiving-increased-funding-as-incidences-of-cancer-grows-581480650

STORM Partners

COMTEX_435876480/2655/2023-06-23T13:09:17

–News Direct–

CEO of EQM Indexes Jane Edmondson joins Natalie Stoberman from the Proactive newsroom to discuss the upcoming index for the new HANetf Future Defence ETF, focused on defence technology and cyber defence.

Edmondson says the index includes elements that reflect the changing nature of modern warfare including augmented reality, artificial intelligence, drones, unmanned vehicles and cybersecurity. Edmondson adds the timing of the ETF launch coincides with a heightened resolve among NATO countries to increase their spending on defence likely driven by global conflicts like the Russia-Ukraine conflict.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/eqm-indexes-of-future-of-defence-etf-index-to-highlight-evolving-landscape-of-defence-technology-744300000

HANetf

COMTEX_435876259/2655/2023-06-23T13:02:52